Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia

SIMPLE SUMMARY: Many patients are still dying from acute myeloid leukemia (AML). Initial treatment of this blood-borne cancer consists of chemotherapy, usually with the agent cytarabine (AraC). However, the cancer cells can become drug resistant and unresponsive to AraC, which complicates further tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönthal, Axel H., Swenson, Steve, Minea, Radu O., Kim, Hye Na, Cho, Heeyeon, Mohseni, Nazleen, Kim, Yong-Mi, Chen, Thomas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305595/
https://www.ncbi.nlm.nih.gov/pubmed/34298603
http://dx.doi.org/10.3390/cancers13143385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305595/
https://www.ncbi.nlm.nih.gov/pubmed/34298603
http://dx.doi.org/10.3390/cancers13143385

Ejemplares similares